Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 3/20 | 0.44 |
| ▸ | MMP9 | P14780 | 3/20 | 0.44 |
| ▸ | MMP8 | P22894 | 3/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | MMP3 | P08254 | 2/20 | 0.44 |
| ▸ | CPA3 | P15088 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.37 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1377052 | 0.86 | CPA3 (0.56) | MMP1MMP9MMP8MMP2MMP3 | |
| SCHEMBL7077478 | 0.79 | MMP2 (0.71) | MMP1MMP9MMP8MMP2MMP3 | |
| SCHEMBL1376096 | 0.78 | CPA3 (0.41) | MMP9MMP8CPA3FOLH1BCHE | |
| SCHEMBL7985039 | 0.75 | MMP1 (0.56) | MMP1MMP9MMP8MMP2MMP3 | |
| SCHEMBL7604015 | 0.75 | CPA3 (0.34) | MMP9MMP8MMP2CPA3FOLH1 | |
| SCHEMBL17697191 | 0.71 | MMP2 (0.54) | MMP1MMP9MMP8MMP2MMP3 | |
| SCHEMBL7217329 | 0.71 | MMP2 (0.84) | MMP1MMP9MMP8MMP2MMP3 | |
| SCHEMBL18857497 | 0.71 | BCHE (0.49) | CPA3FOLH1BCHEGRM3 | |
| SCHEMBL7988020 | 0.70 | MMP1 (0.53) | MMP1MMP9MMP8MMP2MMP3 | |
| SCHEMBL7049730 | 0.70 | CPA3 (0.44) | CPA3FOLH1BCHEGRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| JP-2001521512-A | — | — | 2001-11-06 | — | — | JP | claimed |
| EP-1019369-A1 | THIO DERIVATIVES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-07-19 | — | — | EP | claimed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | claimed |
| WO-1998045257-A1 | THIO DERIVATIVES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-15 | — | — | WO | claimed |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| US-12496292-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2025-12-16 | — | — | US | disclosed |
| CN-113453720-B | Dual ligand drug conjugate and uses thereof | 同宜医药（苏州）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| EP-4541378-A2 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | Endocyte, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250108039-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2025-04-03 | — | — | US | disclosed |
| CN-116059392-B | Ligand conjugate and application thereof | 同宜医药（苏州）有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4512426-A1 | COMPOUND AND USE THEREOF | Coherent Biopharma (Suzhou), Limited (CN) | 2025-02-26 | — | — | EP | disclosed |
| WO-2003035688-A2 | TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES | NOVARTIS PHARMA GMBH (AT) | 2003-05-01 | — | — | WO | disclosed |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| EP-1019369-A1 | THIO DERIVATIVES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-07-19 | — | — | EP | disclosed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | disclosed |
| WO-1998045257-A1 | THIO DERIVATIVES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108039-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | MMP1 3306/4885MMP9 2571/4885MMP8 3252/4885 |
| US-12496292-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | MMP1 3306/4885MMP9 2571/4885MMP8 3252/4885 |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | MMP1 115/4885MMP9 55/4885MMP8 59/4885 |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | FOLH1, TRPV6, FOLR1 | MMP1 2169/4885MMP9 880/4885MMP8 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.